Novo Nordisk is to pay $200m upfront to in-license a ‘triple G’ agonist obesity candidate, helping it compete head-to-head with fierce rival Eli Lilly.
Novo Gets Its Own ‘Triple G’ Obesity Drug To Rival Lilly
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
More from Deals
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus